University of Twente-founded MyLife Technologies will commercialise a microneedle-based dermal patch for administering therapeutic compounds.
MyLife Technologies, a Netherlands-based therapeutic patch developer spun out of University of Twente, obtained €300,000 ($340,000) of funding yesterday from Uniiq, an EU-backed proof-of-concept fund for South Holland province.
Founded in 2012, MyLife Technologies has devised a drug delivery patch for the skin that could supplant the need for certain oral drugs and painful injections deep into the muscle.
The patch features ceramic nanoporous microneedle arrays (npMNA) which store active therapeutic compounds such as vaccines, small molecules and peptides.
MyLife claims npMNA will deliver compounds more efficiently than existing methods and improve upon the capabilities of conventional dermal therapeutic plasters.
The approach is based on research led by Regina Lüttge, a former assistant professor at Twente who departed the university in December 2016.
MyLife Technologies had raised an undisclosed amount of funding the previous month from a group of unnamed “informal” investors.
